1. Scrip
  2. >>Digital Technologies
  3. >>AI

Beyond Pill Sensors, Digital Tech Can Provide Insights On How Patients Use Drugs

 
• By Alaric DeArment

During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.

• Source: Shutterstock

When Otsuka Pharmaceutical Co. Ltd. won US Food and Drug Administration approval for the first digital pill, Abilify MyCite (aripiprazole tablets with sensor), in 2017, it was viewed as an important milestone, as it showed the agency’s willingness to consider digital medicines, in this case one that included a sensor to track compliance. But while the drug was a commercial disappointment, the biopharma industry remains interested in using digital technology to better track how patients use drugs.

An 8 November panel at the 2022 BioFuture conference in New York highlighted some of the ways that digital health technology is enabling new advances both in keeping a closer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.

More from Digital Technologies